



OPEN

## Tissue-specific endothelial cell heterogeneity contributes to unequal inflammatory responses

Hasitha Gunawardana<sup>1</sup>, Tahmineh Romero<sup>2</sup>, Ning Yao<sup>2</sup>, Sebastiaan Heidt<sup>3</sup>, Arend Mulder<sup>3</sup>, David A. Elashoff<sup>2</sup> & Nicole M. Valenzuela<sup>1</sup>✉

Endothelial cells (EC) coordinate vascular homeostasis and inflammation. In organ transplantation, EC are a direct alloimmune target. We posited that tissue specific heterogeneity of vascular EC may partly underlie the disparate organ-specific alloimmune risk. We examined the vascular endothelial response to inflammation across six primary endothelial beds from four major transplanted organs: the heart, lung, kidney and liver. First, we reanalyzed a public dataset of cardiac allograft rejection and found that endothelial inflammatory response genes were elevated in human cardiac allograft biopsies undergoing rejection compared with stable grafts. Next, the inducible inflammatory phenotypes of EC from heart, lung, kidney, and liver were characterized in vitro, focused on expression of adhesion molecules and chemokines, and recruitment of allogeneic peripheral blood mononuclear immune cells. Large vessel cardiac EC most highly upregulated VCAM-1, particularly compared with hepatic EC, supported greater leukocyte adhesion and had distinct chemokine profiles after stimulation with cytokines and complement. Differentially expressed gene candidates that are known regulators of cytokine signaling and inflammatory programming were verified in publicly available datasets of organ-specific endothelial transcriptomes. In summary, differential baseline expression of immune regulating genes may contribute to differential vascular inflammatory responses depending on organ.

### Abbreviations

AMR	Antibody-mediated rejection
DEG	Differentially expressed gene(s)
DSA	Donor specific HLA antibody
EC	Endothelial cell
HAEC	Human aortic endothelial cell
HCAEC	Human coronary artery endothelial cell
HCMVEC	Human cardiac microvascular endothelial cell
HLSEC	Human liver sinusoidal endothelial cell
HLA	Human leukocyte antigen
HLA Ab + C'	HLA antibodies and complement
HPAEC	Human pulmonary artery endothelial cell
HPMVEC	Human pulmonary microvascular endothelial cell
HRGEC	Human renal glomerular endothelial cell
HUVEC	Human umbilical vein endothelial cells
PBMC	Peripheral blood mononuclear cell
TCMR	T cell-mediated rejection

Solid organ transplantation is the definitive therapy for patients with end-stage organ failure, patients who would otherwise die without vital organ function. Nearly 40,000 patients received kidney, heart, liver, lung or visceral transplants in the United States in 2019 alone, and more than three-quarters of a million people have been transplanted in the US since 1988. In the last two decades, advances in immunosuppression and surgical techniques have improved short-term and long-term graft, and patient survival post-transplant. However, the

<sup>1</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, 1000 Veteran Avenue, Room 1-520, Los Angeles, CA 90095, USA. <sup>2</sup>Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. <sup>3</sup>Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands. ✉email: npyburn@mednet.ucla.edu

Type	Sample size N=889	Training set (75%) N = 634	Test set (25%) N = 207	Status
Normal	626 (70%)	472 (74.4%)	154	Normal
Rejection -1 (T cell mediated)	55 (6%)	42 (6.6%)	13	Rejection
Rejection -2 (antibody mediated)	160 (18%)	120 (20%)	40	
Injury	48 (5%)	X	X	Excluded
<b>Total analytical sample</b>	<b>841</b>	<b>634</b>	<b>207</b>	

**Table 1.** Description of dataset.

expected length of function of transplanted organs still does not match patient life-expectancy. Consequently, many patients will require multiple transplants in their lifetime, further contributing to the shortage of organs. Moreover, patient management and graft survival are disparate across transplanted organ types. The expected half-life of a kidney transplant is 8–12 years and of a heart allograft 10–13 years, while lung and bowel grafts fare particularly poorly with 50% failure around 5 years. One major limitation to long-term transplant success is rejection of the donor organ due to recognition of alloantigen, via cellular or antibody/complement-mediated immune attack of the donor tissue. Cardiac and lung transplant recipients experience higher rates of acute and chronic rejection and rejection-attributable graft failure compared with liver allograft recipients, despite lower immunosuppression burdens in liver transplantation<sup>1–3</sup>.


Many cell types are involved in the alloimmune process of allograft rejection, including recipient innate and adaptive immune cells, donor parenchymal cells, and donor vascular cells<sup>4–6</sup>. Modern mainstay immunosuppression primarily targets activation (calcineurin-dependent) and proliferative signaling in the recipient's T cell compartment, but does not prevent function of these other cellular players<sup>7</sup>. The infiltration of recipient leukocytes into the donor tissue is an important early manifestation and pathogenic response in transplant rejection, and is a process tightly regulated by endothelial cell function. Vascular endothelial cells (EC) actively regulate local inflammation, by upregulating adhesion molecules and secreting chemokines which promote leukocyte trafficking<sup>8</sup>. Donor endothelial cells are the first allogeneic cell encountered by the recipient's immune system, at the direct interface in contact with the recipient's perfused blood. Although the liver is generally considered to be “tolerogenic,” specific mechanisms therein contributing to lower transplant rejection rates have not been fully elucidated. Recent work has revealed that vascular EC exhibit tissue-specific molecular and functional heterogeneity<sup>9–16</sup>. Yet, whether there are divergent mechanisms by which EC govern leukocyte recruitment to the site of inflammation are not well-established. The majority of research investigating endothelial inflammation and leukocyte trafficking has employed cells from the descending aorta, neonatal foreskin, muscle or umbilical vein (HUVEC), which are not representative of organ-resident endothelium. Therefore, it is of high interest to determine whether there is also tissue-specific variation in endothelial regulation of inflammation.

We posited that the positional identity of thoracic endothelium differs from that of the liver endothelium in response to inflammatory stimuli and resultant leukocyte recruitment. EC from different anatomic locations exhibited distinct inflammatory phenotypes with respect to the magnitude and kinetics of inducible gene expression, particularly comparing endothelium of the heart to liver microvasculature. In addition, differential endothelial cell responses occurred to anti-HLA antibodies and human complement in an in vitro model of acute antibody-mediated injury. Finally, we identify 37 differentially expressed immune-related genes (DEGs) across ECs from different anatomic origins, which were confirmed in public datasets of murine and human endothelial gene expression.

## Results

**Endothelial cell inflammatory markers are increased in cardiac allograft rejection.** In order to understand the inflammatory changes during transplant rejection, we performed an analysis of bulk transcript expression from publicly available datasets of clinical heart allograft biopsies. Grafts with histological diagnosis of rejection (acute cellular rejection (ACR) and antibody-mediated rejection (AMR)) were compared to normal grafts [GSE124897<sup>17</sup>]. Cardiac allograft biopsy data was divided into training (75%) and test (25%) sets based on the distribution of rejection/normal and rejection type (Table 1). Next, weighted gene co-expression network analyses (WGCNA) procedure grouped the top 5,000 genes into 4 modules and 1 unassigned (Grey) module (Fig. 1a). The Turquoise Module is the largest module with 4,314 genes and showed the highest correlation with rejection versus normal ( $r = 0.77$ ,  $p < 0.001$ ). Genes in this module were enriched in immune response and leukocyte activation, and were increased in rejection compared to normal biopsies (Figs. 1b, S1). Gene ontology analysis<sup>18</sup> showed that 50 genes within the Turquoise Module were involved in cell–cell adhesion, and 11 in leukocyte cell–cell adhesion. The full gene list is available in Supplementary File 1.

To gain insight into the vascular component of the rejection response, we delved further into this gene module to understand whether inflammatory cytokines and their known inducible endothelial immune response genes were altered during rejection. Transcripts for the inflammatory cytokines TNF $\alpha$  and IL-1 $\beta$  were significantly increased in rejection compared with normal biopsies (TNF $\alpha$ : TCMR, 2.31-fold; AMR, 2.25-fold; IL-1 $\beta$ : TCMR, 1.30-fold; AMR, 1.68-fold;  $p < 0.0001$ ) (Fig. 1c). Since TNF $\alpha$  and IL-1 $\beta$  activate inflammatory responses in EC and initiate recruitment of leukocytes, we assessed endothelial adhesion molecules and chemokines. The endothelial adhesion molecule VCAM-1 was elevated 4.08-fold in TCMR and 3.70-fold in ABMR ( $p < 0.0001$  compared to normal). Other adhesion molecules, SELE (E-selectin), ICAM1, BST2 and CD164 (endolyn), and chemokines CCL2/MCP-1, CXCL8/IL-8, CXCL1/GRO $\alpha$ , CXCL10/IP-10, and CXCL9/MIG, were also higher



**Figure 1.** Weighted Correlation Network Analysis of transcript changes within cardiac allograft biopsies with rejection versus stable [GSE124897]. **(a)** Gene dendrogram and module colors for the top 5,000 genes with the most significant Wilcoxon test  $p$  value, comparing rejection to non-rejection/normal. The top 4 modules (turquoise, yellow, blue and brown) are shown. The branches indicate modules of interconnected gene groups. **(b)** Distribution of expression of genes within the Turquoise Module in biopsies with rejection versus non-rejection/normal. **(c–e)** Violin plots show the expression of inflammatory effector molecules and of leukocyte receptors for endothelial adhesion molecules in normal cardiac transplant biopsies and those with TCMR or ABMR. The backtransformed values for intra-graft **(c)** proinflammatory cytokines TNF and IL1B. **(d)** endothelial adhesion and recruitment genes VCAM1, BST2, CD164/endolyn, CXCL1/GRO $\alpha$ , CXCL9/MIG, CXCL10/IP-10, CCL2/MCP-1, CXCL8/IL-8; and **(e)** cognate leukocyte receptors SELPG/PSGL-1, ITGB2/LFA-1/Mac-1, and ITGA4/VLA-4 are shown.




Figure 1. (continued)

in rejection biopsies (Fig. 1d). Further, leukocyte receptors for endothelial adhesion mediators, ITGA4/VLA-4, CX3CR1, SELPLG/PSGL-1 and ITGB2/LFA-1/Mac-1 were significantly enriched in abnormal biopsies (Fig. 1e). An inflammation and immune response module (Turquoise) correlated with rejection included many genes involved in vascular inflammation and leukocyte recruitment. These data show that cardiac allografts undergoing rejection had increased expression of transcripts associated not only with quiescent endothelial markers, as reported<sup>17</sup>, but also effector molecules commonly upregulated during endothelial inflammatory activation and leukocyte recruitment.

**Cytokine-induced endothelial activation.** *Allogeneic PBMC adhesion.* Both TNF $\alpha$  and IL-1 $\beta$  transcripts were significantly increased in cardiac allografts with rejection compared with stable grafts. These proinflammatory cytokines have well-known effects on vascular endothelial cells. Therefore, primary EC from human heart, lung, kidney and liver were left untreated or stimulated with TNF $\alpha$  or IL-1 $\beta$  for 4 h or 18 h in vitro. We measured subsequent adherence of primary allogeneic peripheral blood mononuclear cells (PBMC) to endothelial cells from different vascular beds, using an immunophenotyping adherence assay we developed. The gating strategy is presented in Figure S2. Binding of PBMC increased by 1.51-fold ( $p < 0.0001$ ) when EC were pre-treated with TNF $\alpha$  for 4 h, and 1.48-fold at 18 h (Figs. 2a,b show aggregate results across EC types).

We next used immunophenotyping by flow cytometry to determine the relative proportions of T cells, B cells, NK cells and monocytes adherent to endothelium. The proportion of T cells in the adherent fraction increased an average of 3.76-fold by endothelial activation with TNF $\alpha$  (4 h) (Figure S3a). Similarly, the proportions of adherent B cells, NK cells and monocytes were also significantly increased when endothelial cells were pre-activated with TNF $\alpha$  (Figure S3a). Cycloheximide (CHX) pre-treatment of EC prior to TNF $\alpha$  activation abrogated leukocyte adhesion, demonstrating that recruitment of PBMC was dependent on new endothelial transcription (*data not shown*).

We then specifically compared allogeneic PBMC adhesion to EC from the heart, lung, liver and kidney. We quantitated the ratio of adherent T cells (Fig. 2c), B cells (Fig. 2d), NK cells (Fig. 2e) and monocytes (Fig. 2f) to endothelial cells from different tissue sources in each experiment. Liver endothelium supported the lowest recruitment of overall PBMC to TNF $\alpha$  or IL-1 $\beta$ , as well as individual subsets of T cells and B cells, but not NK cells and monocytes. For example, there was a  $7.1 \pm 3.8$ -fold increase in T cells adherent to HAEC with TNF $\alpha$  4 h compared with only a  $2.03 \pm 0.4$ -fold increase in PBMC adherent to HLSEC under the same conditions (Fig. 2c). Similarly, B cell adhesion to TNF $\alpha$  activated HAEC was increased by  $9.03 \pm 4.5$ -fold, but only  $1.99 \pm 0.39$ -fold for HLSEC. The differences were most pronounced at 4 h (Figure S3b–e), although 18 h stimulation of endothelial cells with TNF $\alpha$  or IL-1 $\beta$  also showed lower adherence of PBMC to HLSEC compared with other EC types (Figure S3f–i). These results show that endothelial cells from the liver exhibit lower adherence of allogeneic lymphocytes after cytokine activation, illustrating the heterogeneity of EC in response to inflammatory stimuli.


*Chemokines.* We focused on chemokine mRNA induction (4 h, Fig. 3a) and secretion (18 h, Fig. 3b) in thoracic and hepatic EC activated with TNF $\alpha$  or IL-1 $\beta$ . Comparing across endothelial cell types, there was no overt impairment of liver endothelium to produce the canonically TNF $\alpha$  or IL-1 $\beta$ -responsive chemokines like CXCL8/IL-8, CCL2/MCP-1 and CXCL1/GRO $\alpha$  (Fig. 3a,b). Yet, we did observe differential patterns of production of other chemokines. For example, unstimulated heart and lung EC constitutively expressed CXCL12/SDF-1, while liver EC expressed comparatively lower levels (Fig. 3a). Aortic, coronary artery and pulmonary artery EC produced less CCL5/RANTES in response to TNF $\alpha$  compared with microvascular endothelium, which was observed at both the mRNA level and in secreted protein (mRNA: Fig. 3c, protein: Fig. 3d). Moreover, CX3CL1/fractalkine production after cytokine stimulation was low in both HAEC and HLSEC, compared with other vascular beds (mRNA: Fig. 3e, protein: Fig. 3f). Discrete mRNA counts for all chemokine genes are presented in Figure S4a–o.

*Adhesion molecules.* Because there was no apparent defect in liver endothelium to produce chemokines in response to inflammatory cytokine activation to account for the reduced adherence of PBMC, we next compared induction of adhesion molecules in vitro at the mRNA (4 h, Fig. 4a) and protein (4–24 h, Fig. 4b–g) levels. Normalized mRNA counts for adhesion molecule genes can be found in Figure S5. All EC expressed a low but detectable level of cell surface ICAM-1, ICAM-2 and BST2. Untreated endothelium was negative for VCAM-1, E-selectin and CD164/endolyn.

Neither TNF $\alpha$  nor IL-1 $\beta$  changed expression of BST1, ICAM2 or BST2 at 4 h (Fig. 4a, S4f–h). Although CD44 and CD164/endolyn were modestly enhanced by TNF $\alpha$  stimulation, there was no notable difference across endothelial cell types at the times assessed (Fig. 4a).

E-selectin expression was transiently increased by TNF $\alpha$ , peaking around 6 h and declining nearly to baseline after 18 h of TNF $\alpha$  stimulation. Across EC types, liver endothelium consistently exhibited the lowest inducible E-selectin expression (HAEC  $45.6 \pm 22.74$ -fold; HCAEC  $46.5 \pm 28.7$ -fold; HLSEC  $15.9 \pm 7.81$ -fold;  $p < 0.0001$  comparing HLSEC versus others;  $n = 5$  donors at 4 h) in response to both TNF $\alpha$  and IL-1 $\beta$  (Fig. 4b,c). To gain insight into whether the diminished E-selectin induction in liver endothelial cells was specific to the stimulus, we tested whether there were differences in thoracic versus hepatic endothelial cells to respond to another stimulus of E-selectin. It has also been reported that endothelial cells upregulate E-selectin in response to IL-10. We observed that IL-10 stimulated increased E-selectin expression on aortic EC, but no E-selectin was detected on liver endothelium stimulated with IL-10 (*data not shown*).

ICAM-1 was expressed at low levels on untreated endothelial cells and highly upregulated by either TNF $\alpha$  or IL-1 $\beta$  at 18 h. Unlike E-selectin, there was no difference across endothelial cell types in the kinetics or magnitude of ICAM-1 induction (Fig. 4d,e).



◀ **Figure 2.** Differential adherence of allogeneic PBMC to cytokine-activated endothelial cells. Endothelial monolayers were stimulated with TNF $\alpha$  (20 ng/mL) or IL-1 $\beta$  (20 ng/mL) for 4 h or 18 h. Stimulation medium was removed, and whole PBMC fractions were added at a ratio of 3 PBMC to 1 endothelial cell and allowed to adhere for 45 min. Nonadherent cells were removed by two washes with HBSS with Ca $^{2+}$  and Mg $^{2+}$ , and adherent cells were detached by a third wash with PBS without Ca $^{2+}$  and Mg $^{2+}$  followed by treatment Accutase. Adherent cells were stained with an immunophenotyping panel and acquired by flow cytometry. (a) Endothelial cells and total PBMC as a percent of live cells in the adherent fraction is shown in the spaghetti plots, comparing untreated endothelial cells with (a) TNF $\alpha$  4 h-treated EC and (b) TNF $\alpha$  18 h-treated EC. Each pair represents a unique experiment (n = 21). \*\*\* $p < 0.0001$ . (c) Adherence of T cells (gated on CD105 $^{neg}$  CD3 $^{+}$ ) to endothelial cells (gated on CD11a $^{neg}$  CD105 $^{+}$ ) from different vascular beds after pre-activation with TNF $\alpha$  at 4 h (black bars) or IL-1 $\beta$  at 4 h (grey bars). # $p < 0.1$ , \* $p < 0.05$  comparing HAEC or HCAEC to HLSEC. (d) Adherence of B cells (gated on CD105 $^{neg}$  CD19 $^{+}$ ) to endothelial cells (gated on CD11a $^{neg}$  CD105 $^{+}$ ) from different vascular beds after pre-activation with TNF $\alpha$  at 4 h (black bars) or IL-1 $\beta$  at 4 h (grey bars). # $p < 0.1$ , \* $p < 0.05$  comparing HAEC or HCAEC to HLSEC. (e) Adherence of NK cells (gated on CD105 $^{neg}$  CD3 $^{neg}$  CD19 $^{neg}$  CD56 $^{+}$ ) to endothelial cells (gated on CD11a $^{neg}$  CD105 $^{+}$ ) from different vascular beds after pre-activation with TNF $\alpha$  at 4 h (black bars) or IL-1 $\beta$  at 4 h (grey bars). # $p < 0.1$ , \* $p < 0.05$  comparing HAEC or HCAEC to HLSEC. (f) Adherence of monocytes (gated on CD105 $^{neg}$  CD3 $^{neg}$  CD19 $^{neg}$  CD14 $^{+}$ ) to endothelial cells (gated on CD11a $^{neg}$  CD105 $^{+}$ ) from different vascular beds after pre-activation with TNF $\alpha$  at 4 h (black bars) or IL-1 $\beta$  at 4 h (grey bars). # $p < 0.1$ , \* $p < 0.05$  comparing HAEC or HCAEC to HLSEC. Results are presented as the fold increase in the ratio of PBMC to endothelial cells as mean  $\pm$  SEM (n = 3 unique EC-PBMC donor combinations).

VCAM-1 was not detected on untreated endothelial cells, and its TNF $\alpha$  or IL-1 $\beta$  inducible expression was maximal after 18–24 h of stimulation. Notably, endothelium from the aorta and coronary artery upregulated VCAM-1 earliest (by 4 h), and the magnitude and absolute expression of VCAM-1 was also higher in large vessel cardiac endothelium than other EC types (fold increase at 4 h, HAEC 51.8  $\pm$  13.8-fold, HCAEC 15.70  $\pm$  4.5-fold, HLSEC 10.11  $\pm$  5.6-fold (n = 4); at 18 h, HAEC 65.32  $\pm$  15.7-fold, HCAEC 43.64  $\pm$  12.29-fold, HLSEC 13.68  $\pm$  7.04-fold;  $p < 0.01$  HAEC vs. HLSEC, n = 5) (Fig. 4f,g). We also tested whether cardiac and hepatic endothelial cells differentially responded to another cytokine, IL-4, which is known to stimulate endothelial expression of VCAM-1. Like with TNF $\alpha$ , VCAM-1 mRNA and protein was increased in aortic EC early (19.6-fold 4 h) after IL-4 stimulation, but did not substantially rise in HLSEC at this time point (3.46-fold) (mRNA: Fig. 4h, protein: Fig. 4i). Moreover, total expression and fold induction of VCAM-1 in response to IL-4 was significantly higher on aortic and coronary artery EC compared with liver EC (HAEC 5.59  $\pm$  1.34-fold 4 h, 11.19  $\pm$  2.68-fold 24 h; HLSEC 1.1  $\pm$  0.2-fold 4 h, 5.26  $\pm$  1.58-fold 24 h,  $p < 0.1$ , n = 3).


In summary, liver sinusoidal endothelium exhibited the lowest induction of adhesion molecules E-selectin and VCAM-1, which may contribute to lower adhesion of allogeneic PBMC. Moreover, large vessel cardiac EC upregulated VCAM-1 earlier, and to a greater magnitude, compared with EC from other anatomic origins.

**Complement-induced endothelial cell activation.** Transplant recipients may also develop anti-donor antibodies binding to polymorphic HLA molecules. Such HLA antibodies are deleterious to the allograft, in part because they can activate the classical complement cascade. Complement activation at the target cell surface initiates sequential enzymatic cleavage events, generating inflammatory “split products.” The cascade culminates in deposition of terminal complement split products C5b-9, which are proinflammatory and insert into the target cell membrane. Endothelial cells (HUVEC) are known to respond to complement split products through activation of intracellular inflammatory signaling<sup>19–23</sup>. However, liver allografts are notably resistant to this type of injury in the transplant setting, and whether there exists heterogeneity in the sensitivity of different vascular beds to complement activation has not been determined. We therefore questioned whether endothelial responses to complement mediated injury were unequal.

First, endothelial monolayers were treated with a polyclonal mixture of chimeric and fully human monoclonal antibodies against HLA class I, or with sera from highly sensitized transplant patients, to mimic donor specific HLA antibodies seen in transplant patients; and with normal human serum as a source of exogenous complement (HLA Ab + C). We confirmed that binding of anti-HLA IgG triggered complement activation by measuring deposition of terminal complement SC5b-9 on the cell surface after 20 min and 1 h (Figure S6a–d) which was similar across HAEC, HCAEC and HLSEC, and production of C5a in the supernatant (*data not shown*).


**Chemokines and adhesion molecules.** We used this stimulation system to model endothelial cell activation by antibody-mediated complement damage. When exposed to HLA antibodies and human complement (HLA Ab + C), endothelial cells enhanced expression of inflammatory genes over time (Figure S6e). As a control, HLA antibodies added with inactivated complement had a lower response compared with antibodies added in active complement (Figure S6e). Similarly, exposure to a control monoclonal chimeric antibody to endoglin (anti-CD105 hIgG1) or isotype control non-binding anti- $\beta$ -gal hIgG1 had no effect (Figure S6f).

EC upregulated 78 and 76 genes at 4 h and 24 h, respectively, of stimulation with monoclonal HLA Ab + C (Fig. 5a). We focused on induction of proinflammatory genes that contribute to adhesion of leukocytes. Comparing primary cardiac and liver endothelium, there were both universal and cell-type specific patterns of chemokine production by EC activated with HLA antibodies and human complement. For example, secreted levels of IL-6, GRO $\alpha$ , CXCL8/IL-8, CCL2/MCP-1, and CCL4/MIP-1 $\beta$  were comparable across EC types, but HAEC upregulated chemokines CCL2/MCP-1 and CXCL1/GRO $\alpha$  to a greater extent than HLSEC (mRNA: Fig. 5b, protein: Fig. 5c), and adhesion molecules E-selectin, VCAM-1 as well (mRNA: Fig. 5d,e). HLSEC again had the lowest




**Figure 3.** Chemokine and cytokine production by cytokine-activated endothelial cells. Endothelial monolayers were stimulated with TNF $\alpha$  (20 ng/mL) or IL-1 $\beta$  (20 ng/mL). (a) After 4 h, stimulated endothelial cells were lysed in RLT buffer, and mRNA for immune response genes was measured by Nanostring. Results are presented in the heat map, with hierarchical clustering and color scale representing relative mRNA counts of each chemokine across conditions. Heat maps is transformed by row min/max with hierarchical clustering using one minus Pearson correlation and grouped by stimulus. (b) After 18 h, conditioned media were tested for secreted factors by Luminex and ELISA. Results are presented in the heat map, with hierarchical clustering and color scale normalized to represent relative protein concentrations (pg/mL) of each secreted chemokine protein across conditions (n = 5). (c) Normalized mRNA counts for CCL5 (RANTES) gene expression across endothelial cells stimulated for 4 h with TNF $\alpha$  or IL-1 $\beta$ . (d) Fold increase in the concentration of secreted RANTES (CCL5) protein after 18 h across endothelial cells (n = 3). Results are presented as mean  $\pm$  SEM. TNF $\alpha$ -induced RANTES was significantly lower from HAEC and HCAEC compared with HCMVEC, HPMVEC, and HLSEC (all  $p < 0.001$ , by two way ANOVA followed by Tukey's multiple comparison's test). IL-1 $\beta$ -induced RANTES was significantly lower from HAEC than microvascular EC ( $p < 0.05$ ). (e) Normalized mRNA counts for CX3CL1 (fractalkine) gene expression across endothelial cells stimulated for 4 h with TNF $\alpha$  or IL-1 $\beta$ . (f) Concentration of secreted fractalkine (CX3CL1) protein after 18 h across endothelial cells measured by Luminex (n = 4). Results are presented as mean  $\pm$  SEM. IL-1 $\beta$ -induced fractalkine was significantly lower from HAEC and HLSEC compared with HCAEC and HPMVEC (all  $p < 0.05$ , by two way ANOVA followed by uncorrected Fisher's LSD).





**Figure 4.** Adhesion molecule expression by cytokine-activated endothelial cells. **(a)** After 4 h activation with TNFα (20 ng/mL) or IL-1β (20 ng/mL), stimulated endothelial cells were lysed in RLT buffer, and mRNA for immune response genes was measured by nanostring. Absolute mRNA counts for endothelial adhesion molecule genes are presented in the heat map. **(b, c)** After 4 h or 18–24 h, stimulated endothelial cells were detached and TNFα **(b)** and IL-1β **(c)** induced cell surface E-selectin was measured by flow cytometry. Results are presented as fold increase in the median fluorescence intensity of cell surface E-selectin, normalized within each experiment to the untreated condition for each cell type. **(d, e)** After 4 h or 18–24 h, stimulated endothelial cells were detached and TNFα **(d)** and IL-1β **(e)** induced cell surface ICAM-1 was measured by flow cytometry. Results are presented as fold increase in the median fluorescence intensity of cell surface ICAM-1, normalized within each experiment to the untreated condition for each cell type. **(f, g)** After 4 h or 18–24 h, stimulated endothelial cells were detached and TNFα **(f)** and IL-1β **(g)** induced cell surface VCAM-1 was measured by flow cytometry. Results are presented as fold increase in the median fluorescence intensity of cell surface VCAM-1, normalized within each experiment to the untreated condition for each cell type. (TNFα and IL-1β 4 h, n = 4; 18–24 h, n = 5–6 donors per endothelial cell type). #*p* < 0.1, \**p* < 0.05, \*\**p* < 0.001 comparing HAEC and HCAEC to HLSEC by two way ANOVA followed by uncorrected Fisher’s LSD. **(h)** mRNA and **(i)** fold increase in the MFI of cell surface expression of VCAM-1 was measured on aortic HAEC and liver HLSEC endothelial cells stimulated with IL-4 (20 ng/mL) for 4 h or 24 h (n = 3 donors per endothelial cell type). Results are presented as mean ± SEM. #*p* < 0.1 comparing HAEC to HLSEC, by two way ANOVA and uncorrected Fishers LSD.



**Figure 4.** (continued)

overall induction of E-selectin and VCAM-1 among all EC types tested (Fig. 5d, S7a,b). In order to confirm the relevance of these results, we also tested endothelial cells stimulated with sera from allosensitized transplant patients (Figure S8). Here, too, liver endothelial cells showed a dampened response to complement-induced inflammation. As a control, negative serum without HLA antibodies did not bind to or activate EC (Figure S8).

These results demonstrate that cardiac EC respond to HLA Ab + C by upregulation of adhesion molecules and chemokines, while liver endothelium exhibits a lower response.

**Endothelial heterogeneity of immune-related gene expression.** Finally, we sought to determine whether heterogeneity of baseline gene expression across endothelial cell types could contribute to tissue specific chemokine and adhesion molecule induction patterns. Therefore, we analyzed gene expression across untreated primary endothelial cell types ( $\geq 5$  different donors per cell type) to identify possible mediators of differential inflammatory responses. Liver endothelial cells were compared against the five other types independently (Fig. 6a–e) and to the other six endothelial cell types as a group (Fig. 6f, Table S6). Thirty-seven of 579 immune-related genes were differentially expressed at baseline comparing at least one endothelial cell against liver endothelium or HLSEC to all other EC as a group ( $p < 0.05$ ;  $FC > 1.5$ ; minimum count 250).

We leveraged publicly available datasets of murine and human endothelial gene expression to corroborate our findings<sup>11–13,15,16,24–26</sup>. Eighteen of the 37 candidate DEGs were also confirmed in public datasets, and ten intersected with transcripts found in rejecting human cardiac allograft biopsies [GSE124897,<sup>17</sup>] (Table 2). Two of these DEGs were suppressors of cytokine signaling (SOCS) family proteins, SOCS1 and SOCS3, and two other genes, TNFAIP3/A20 and BCL6, are known repressors of NFκB and JNK signaling.

Of the 37 DEGs initially identified in our data, 28 were differentially expressed in two or more EC versus HLSEC, and 17 were confirmed as significantly differentially expressed across EC in at least two other data sets of endothelial cell heterogeneity. Results are presented in Table 2. DEGs included markers of liver sinusoids (FCGR2B), as well as endothelial genes more lowly expressed in the hepatic microvasculature (PECAM1, CDH5). Other DEGs were regulators of cytokine signaling or complement activation, including BCL6 and CFH (highest in cardiac EC), CD55, IL6ST, IL1A, TNFAIP3, and TNFAIP6 (highest in liver), SOCS3 (highest in lung) and TNFSF10 (lowest in liver). CD55, TNFAIP3 and TNFAIP6 were confirmed enriched in liver compared with non-liver EC in multiple public datasets of endothelial transcriptomes [GDS4777, GSE47067<sup>13,26</sup>]. Similarly, BCL6 and TNFSF10 (TRAIL) were confirmed lower in liver EC<sup>25,26</sup>, and were specifically enriched in cardiac endothelium but not hepatic EC<sup>24</sup>. Ten genes were also present in the Turquoise immune response module in cardiac allograft biopsies, distinguishing rejection from stable allografts.

## Discussion

The divergent responses of endothelial cells from different organs and vascular beds remain incompletely characterized, and the underlying mechanisms are poorly understood. We hypothesized that heterogeneity of endogenous negative regulators of inflammatory signaling controls the diversity of endothelial response to inflammatory stimuli. The aim of this study was to characterize the basal and inducible inflammatory phenotypes of EC from heart, lung, kidney, and liver (arterial and microvascular), including expression of adhesion molecules and chemokines, and recruitment of allogeneic peripheral blood mononuclear immune cells. We provide evidence that EC from different anatomic locations exhibited distinct inflammatory phenotypes with respect to the magnitude, kinetics and durability of inducible gene expression, particularly comparing large vessels of the heart to liver microvasculature. We further demonstrate that differential endothelial cell responses occur to transplant-relevant chimeric human anti-HLA antibodies and human complement in an *in vitro* model of acute antibody-mediated rejection.

Early histology studies showed that endothelial adhesion molecules are increased in human and rodent allografts during rejection<sup>8,27,28</sup>. Our analysis of cardiac allograft biopsies confirmed at the molecular level that endothelial inflammatory genes are increased in rejection. Twenty-five years ago, Steinhoff et al. observed that endothelial adhesion molecule expression in normal and rejecting heart and lung allografts varied not only between organs, but also across vascular beds within each organ<sup>29</sup>. In contrast, sinusoids in liver allografts failed to upregulate E-selectin or VCAM-1<sup>30</sup>. However, these observations were not explained by follow-up mechanistic studies. Our findings suggest that organotypic differences of endothelial cells (EC) may contribute to the relative resistance or susceptibility of transplanted tissue. In particular, liver endothelial cells are intrinsically less likely to promote inflammation. Identification of the protective mechanisms within the liver vascular compartment would reveal new therapeutic targets to reduce rejection in other organs.

EC are key targets of alloimmunity and coordinate access of allogeneic leukocytes to the allograft. It is clear from expanding literature on the heterogeneity of endothelial cell phenotype and function that EC from different vascular beds exhibit important variation in their gene expression, morphology and response to stimuli<sup>11–16,25,31–33</sup>. Our central hypothesis was that EC from different organs, and vascular beds within each organ, exhibit functional diversity that contributes to response to injurious stimuli in transplantation.


Some limited prior work has shown unequal inflammatory responses comparing select EC types<sup>34–36</sup>. For example, differential patterns of adhesion molecule expression by endothelium from different organs have been observed in response to LPS/shock<sup>11,12,37</sup> and inflammatory cytokines<sup>9,36,38,39</sup>. Although these studies provide evidence of differential gene expression at baseline and some inducible conditions, most compared only a few vascular beds and gave little insight into the mechanisms of differential responses. Our results further resolve that EC from the large vessels in the heart (aorta and coronary artery) exhibit the highest VCAM-1 induction by TNF $\alpha$  and IL-1 $\beta$ , and provide novel evidence that liver EC have the lowest response to not only inflammatory cytokines, but also HLA antibody-triggered complement activation.

Interestingly, our results show differential chemokine production by endothelium from different vascular beds. Chemokines show preferential recruitment of different immune cell subsets depending on leukocyte expression of the chemokine receptor<sup>40</sup> as well as local tissue specific patterns. Chemokines promote firm adhesion of leukocytes to endothelial cells, augmenting the signals from adhesion molecules<sup>41</sup>. Endothelial MCP-1 and IL-8 are widely and strongly induced by both TNF $\alpha$  and IL-1 $\beta$ , and promote infiltration of innate leukocytes such as monocytes and neutrophils. On the other hand, CCL5 (RANTES) can also recruit CCR5-bearing T lymphocytes. The specific arrays of chemokine elaboration by different vascular beds are therefore intriguing in the broader context of endothelial control of the quality of local immune responses.

In clinical transplantation, cardiac allografts are more subject to hyperacute, acute and chronic rejection caused by donor specific antibodies compared with liver transplants. We reported that complement anaphylatoxins enhance aortic EC activation<sup>22</sup>. Sublytic MAC, C3a or C5a-treated HUVEC also produced chemokines<sup>42</sup>, ICAM-1<sup>43</sup>, VCAM-1 and E-selectin<sup>20</sup>, mediated in part by NF $\kappa$ B/NLRP3. Although differential complement activation between renal and brain EC was observed<sup>44</sup>, different responses to complement had not yet been evaluated for EC resident within transplanted organs. Using high titer monoclonal HLA antibodies, patient sera and exogenous complement, we show that thoracic EC exhibited greater expression of adhesion molecules and unique patterns of chemokine production in response to complement activation, compared with liver endothelium. Future studies are needed to understand the activation threshold of EC to lower titers or fewer clones of HLA antibodies and complement.

Bulk endothelial transcriptomes from human fetal heart, lung, liver, kidney<sup>14</sup>; and from mouse heart, liver, kidney and lung<sup>11,12,16</sup> have revealed both shared characteristic endothelial signatures and tissue specific gene expression. A major recent breakthrough in understanding of endothelial diversity across organs *in vivo*, predominantly performed in mice, has arisen from single cell sequencing, for example the *Tabula Muris*<sup>26</sup>, and followed with even greater resolution of cells throughout the body by Kalucka and colleagues<sup>13</sup>. We capitalized on these data to examine differential expression of immune-related genes among EC from different anatomic origins. Several studies have compared the transcriptional profiles of freshly isolated and cultured EC<sup>10,11,45</sup>. Some of the differential signatures were lost after extended culture, indicating a contribution of microenvironment in site-specific identity or convergence due to culture conditions. Yet, a subset of markers were retained even after culture, which may represent the intrinsically specified differences<sup>10,11</sup>. Bulk endothelial transcriptomes from human fetal organs<sup>14</sup> and mouse organs<sup>11,12,16</sup>, and single cell sequencing in mice<sup>13,26</sup> have revealed characteristic endothelial signatures and tissue specific gene expression. We leveraged these multiple public transcriptome datasets to confirm differentially expressed immune-related genes among both cultured and freshly isolated EC.

Certainly multiple cell sources could contribute to gene expression in biopsies, and cell type deconvolution of the transcript signatures of rejection will be an important next step to drill down on compartmentalized responses



◀ **Figure 5.** Endothelial cell activation by HLA antibody and complement. Endothelial cell monolayers were treated with a polyclonal mixture of anti-HLA I antibodies in the presence of 25% intact human serum complement for 4 h or 24 h. **(a)** Stimulated endothelial cells were lysed in RLT buffer, and mRNA for immune response genes was measured by nanostring. Volcano plots demonstrate changes in gene expression across the 6 primary endothelial cells stimulated with HLA + C' for 4 h (left panel) and 24 h (right panel). **(b)** After 4 h and 24 h exposure to HLA + C, mRNA expression of chemokines was measured by Nanostring ( $n = 1$ ). Results are presented in the heat map, with hierarchical clustering and color scale representing relative mRNA counts of each chemokine across conditions. **(c)** After 4 h or 24 h treatment with DSA + C, conditioned media were tested for secreted factors by Luminex and ELISA. Results are presented in the heat map, with color scale representing fold increase in protein concentrations (pg/mL) of each chemokine compared to untreated. **(d)** Mean fold increase in the MFI of cell surface E-selectin, ICAM-1 and VCAM-1 across HAEC, HCAEC and HLSEC is shown, after stimulation with HLA monoclonal antibodies and intact human complement for 4 h ( $n = 3$  donors per endothelial cell type). Results are presented as mean  $\pm$  SEM.  $*p < 0.05$ ,  $***p < 0.0001$  comparing HLSEC to HAEC, by two way ANOVA and uncorrected Fisher's LSD. E-selectin: HAEC versus HLSEC  $p < 0.001$ ; HCAEC versus HLSEC  $p = 0.038$ . VCAM-1: HAEC versus HLSEC  $p = 0.0212$ ; HCAEC versus HLSEC  $p = 0.0175$ . **(e)** Mean fold increase in the MFI of cell surface E-selectin, ICAM-1 and VCAM-1 across HAEC, HCAEC and HLSEC is shown, after stimulation with HLA monoclonal antibodies and intact human complement for 24 h ( $n = 3$  donors per endothelial cell type). Results are presented as mean  $\pm$  SEM.  $*p < 0.05$ ,  $***p < 0.0001$  comparing HLSEC to HAEC, by two way ANOVA and uncorrected Fisher's LSD.

during alloimmune injury. Additional work is also ongoing to elucidate the role of the candidates identified by our DEG analysis in the regulation of endothelial cell inflammation.

Our results add to the existing literature that EC from the large vessels in the heart (aorta and coronary artery) exhibit the highest VCAM-1 induction by TNF $\alpha$  and IL-1 $\beta$ , and provide novel evidence that liver EC have the lowest response to not only inflammatory cytokines, but also HLA antibody-triggered complement activation. Large vessel arteries experience higher shear stress, which may account in part for the biological need of higher VCAM-1 expression to support adhesion in the aorta and arteries compared with lower shear flow microvascular endothelium. Although differential complement activation between renal and brain EC was reported<sup>44</sup>, this question had not yet been evaluated for EC resident within transplanted organs. Our experiments expand beyond these previous studies to describe the long-term differential responses of tissue resident EC depending on anatomic origin, with carefully controlled conditions with monoclonal HLA antibodies, patient sera and exogenous complement.

Among the candidate genes we identified, complement regulatory factors like CFH, which encodes a soluble inhibitor of complement C3b generation, and CD55, also known as decay accelerating factor, were significantly differentially expressed by liver endothelium compared to thoracic EC. Other differentially expressed genes included transcriptional modifiers, repressors and negative feedback regulators of inflammatory and cytokine signaling, including BIRC3, BCL6, SOCS1, SOCS3, TNFAIP3 and TNFAIP6. Interestingly, many of the differentially expressed genes were also inducible by inflammatory cytokines and/or DSA + C, and were modified by NF $\kappa$ B inhibition. It is tempting to speculate that some differentially expressed genes function in negative feedback regulation of pro-inflammatory signaling in endothelium.


## Materials and methods

**Ethics statement.** All experimental protocols in this study were approved by the UCLA Institutional Review Board (#17-000,477, #12-001,597, #10-001,689). IRB waived the requirement for informed consent under 45 CFR 46.116(d) for the study using discarded samples; informed consent was obtained from volunteers. All methods were carried out in accordance with institutional, state and federal guidelines and regulations.

**Cells.** The immortalized human dermal microvascular cell line HMEC-1 was obtained from ATCC. Primary human aortic endothelial cells (HAEC, Ao) were isolated from the aortic rings of deceased donors as described<sup>46</sup> (kindly provided by Dr. EF Reed, UCLA). Primary HAEC, human coronary artery (HCAEC, CA), cardiac microvascular (HCMVEC, CM), pulmonary artery (HPAEC, PA), pulmonary microvascular (HPMVEC, PM), hepatic sinusoidal (HLSEC, L), and renal glomerular (HRGEC, RG) endothelial cells were obtained from commercial sources (see Supplemental Table 1). Commercial endothelial cells were initially expanded from passage 2–3 in respective vendor-recommended media, then switched to the same complete medium for subculturing. Expression of endothelial markers CD31/PECAM-1, CD105/endoglin and CD146/MCAM was verified by flow cytometry. All cells were cultured in tissue culture-treated vessels coated with 0.2% porcine gelatin (Sigma-Aldrich) in 37 °C, and 5% CO<sub>2</sub>. EC were subcultured at 90% confluence using trypsin/EDTA. Cells were used for experiments between passages 3–8.

For experiments, cells were cultured to confluence in tissue culture-treated, gelatin-coated plates and allowed to rest overnight in complete media. Multiple endothelial cells types were tested in parallel in the same experiment. All endothelial cells were switched to M199 + 10% heat inactivated FBS (HI-FBS) (Hyclone) for the duration of experiments. For 96 well plates, 100 $\mu$ L of medium was added; for 48-well plates, 250 $\mu$ L of medium was added; and for 24-well plates, 500 $\mu$ L medium was added. The next day, cells were stimulated in M199 + 10% HI-FBS alone or with TNF $\alpha$  or IL-1 $\beta$  at the concentrations and times indicated.

Primary peripheral blood mononuclear cells were prepared from the blood of healthy volunteers using Ficoll-Paque density centrifugation. Briefly, whole blood was collected into yellow top ACD tubes or a CPDA-1 blood collection bag and diluted 1:1 in without Ca<sup>2+</sup> or Mg<sup>2+</sup>. 25–30 mL of diluted whole blood was overlaid onto



**Figure 6.** Differential immune gene expression across unstimulated endothelial cells. Volcano plots compare gene expression within each cell type to HLSEC (a–e) and compare HLSEC to all other non-liver endothelium as a group (f). (HAEC, n = 8; HCAEC, n = 4; HCMVEC, n = 7; HPAEC, n = 6; HPMVEC, n = 7; HLSEC, n = 7).

15 mL of Ficoll-Paque Premium (1.078 g/mL, GE Healthcare) and centrifuged at 1800RPM for 20 min with no brake. The white blood cell interface was collected and washed twice with PBS, centrifuging at 300xg for 7 min to remove residual platelets. PBMC were either resuspended in RPMI + 10% HI-FBS and used in experiments on the same day, or frozen in 90% FBS with 10% DMSO. Frozen PBMC were thawed, washed once with RPMI + 10% HI-FBS and allowed to recover in a 37 °C water bath before use in experiments.

**Reagents.** TNF $\alpha$  and IL-1 $\beta$  were obtained from Sigma Aldrich (#H8916, #I9401). Recombinant human carrier-free IL-6, IL-10 and IL-4 were purchased from R&D (#285-IF, #206-IL-010/CF, #204-IL-010/CF, 217-IL-005/CF). Based on the results of preliminary dose–response experiments, the following concentrations of each stimulus were used: TNF $\alpha$  20 ng/mL, IL-1 $\beta$  20 ng/mL, IL-4 (20 ng/mL), IL-10 (20 ng/mL). Cycloheximide (CHX) was obtained from Sigma-Aldrich.

Control antibodies were anti- $\beta$ -galactosidase hIgG1 (Invivogen #bgal-mab1) and anti-CD105 hIgG1 (MediMabs #MM-0300). Chimeric HLA I human IgG1 (derived from murine clone W6/32) was obtained from Invivogen, and HLA I hIgG1, hIgG3 were kindly provided by One Lambda/ThermoFisher. Fully human anti-HLA-A2/A28 (clone SN607D8), anti-HLA-A2/B17 (clone SN230G6), anti-HLA-A1/A3/11 (clones MUL4C8 and MUL2C6), and anti-Bw4 (clone MUS4H4) IgG1 were kindly provided by Drs. Mulder and Heidt (Leiden University Medical Center).

Broadly reactive sera from transplant candidates with a cPRA 99–100% and strong > 10,000 MFI antibodies to common HLA-A and HLA-B antigens were heat-inactivated at 56 °C for 1 h and frozen in aliquots. Discarded patient serum without HLA antibodies by single antigen bead based detection was used as a negative control.

Human complement was obtained from Complement Technologies (cat#NHS). Human serum complement that was heat-inactivated at 56 °C for  $\geq$  30 min, or C1q-depleted or C3-depleted serum was used as a control.

**Flow cytometry immunophenotyping adherent PBMC.** Endothelial cells were seeded at confluence in a tissue culture-treated, gelatin-coated 24 well plate and allowed to rest overnight in complete medium. Peripheral blood mononuclear cells prepared from whole blood as above were added to stimulated endothelial cells at a ratio of 3:1 (based on initial experiments testing 1:1, 3:1 and 5:1 and at concentration consistent with that in whole blood  $10^6$ /mL). After 45 min, nonadherent cells were removed by gentle washing with HBSS with Ca $^{2+}$  or Mg $^{2+}$  followed by one wash with PBS without Ca $^{2+}$  or Mg $^{2+}$ . Remaining adherent cells were detached

Gene	Comparison vs HLSEC	log <sub>2</sub> fold	p value	DEG in turquoise module heart biopsy?	Confirmed DEG in > 2 datasets ?	Public data notes	Data supporting
BCL6	HRGEC	1.85	0.00169		Yes	Enriched heart (large vessel), lowest in liver	(11, 17, 18, 19)
C1R	not HLSEC	-2.58	0.0013		YES	Liver	(7, 18, 19)
	HAEC	-3.47	7e-05				
	HCMVEC	-4.32	3.7e-06				
	HPAEC	-3.87	3.3e-05				
	HPMVEC	-3.05	3.3e-04				
	HRGEC	-3.47	1.3e-04				
C1S	not HLSEC	-2.55	0.026				(18, 19)
	HAEC	-3.84	0.00114				
	HCAEC	-5.05	0.00663				
	HCMVEC	-5.64	1.1e-05				
	HPMVEC	-4.64	0.00010				
CCL20	HAEC	-3.47	0.00303				
	HCMVEC	-5.64	0.0133				
	HRGEC	2.52	0.00748				
CD24	HCAEC	6.51	7.2e-07		Yes	Kidney	(18, 19)
	HCMVEC	2.45	0.0129				
CD34	not HLSEC	2.47	0.00817		Yes	Lowest liver	(12, 18, 19)
	HCAEC	4.07	0.00051				
	HCMVEC	3.68	0.00027				
	HRGEC	3.07	0.0027				
CD36	HAEC	-2.32	0.0313		Yes	Lowest kidney	(9, 12, 18, 19)
	HCAEC	2.76	0.0305				
	HPMVEC	3.45	0.00217				
	HRGEC	-3.18	0.00696				
CD55	not HLSEC	0.926	0.143		Yes	Liver	(9, 18, 19, GSE48209)
	HRGEC	2.68	0.000018				
CDH5	not HLSEC	0.889	0.117	Yes			(18)
	HRGEC	2.61	0.0001				
CEBPB	HAEC	-1.51	0.0164				(17, 18, 19)
	HCMVEC	-1.51	0.0177				
	HPMVEC	-1.43	0.0256				
CFH	not HLSEC	2.04	0.00179		Yes	Heart	(7, 18, 19)
	HAEC	1.76	0.00713				
	HCAEC	2.10	0.00796				
	HPAEC	3.49	6.3e-06				
	HRGEC	2.05	0.00387				
FCGR2B	HAEC	-2.94	0.00929	Yes*	Yes	LIVER	(9, 18, GSE48209)
	HPAEC	-2.37	0.00122				
	HRGEC	-3.05	0.00486				
IFIT2	HRGEC	3.58	0.000394	Yes	Yes	Kidney	(9, 18, 19)
IFITM1	HAEC	-3.64	0.000191	Yes		Heart IFN signature	(9, 18)
	HCAEC	-4.32	0.000233				
	HCMVEC	-3.32	0.000625				
	HPMVEC	-2.25	0.0158				
IL1A/IL1B	not HLSEC	-3.14	0.0013	Yes*	Yes	Liver	(12, 18, 19, GSE48209)
	HAEC	-2.0	0.108				
	HCAEC	-3.47	0.00173				
	HCMVEC	-2.64	0.002				
	HPAEC	-5.52	0.000041				
	HPMVEC	-2.94	0.00108				
	HRGEC	3.64	0.000272				
IL6ST	HRGEC	2.11	3.9e-05		Yes	Liver	(9, 17, 18, 19)

Continued

Gene	Comparison vs HLSEC	log <sub>2</sub> fold	p value	DEG in turquoise module heart biopsy?	Confirmed DEG in > 2 datasets ?	Public data notes	Data supporting
LIF	HAEC	-4.64	4.9e-06				(12)
	HCAEC	-4.05	4.9e-04				
	HCMVEC	-4.05	4.3e-05				
	HPMVEC	-2.83	2.8e-03				
LITAF	HAEC	-1.68	0.0097	Yes			
	HCAEC	-2.64	0.00126				
	HCMVEC	-1.69	0.0133				
	HPMVEC	-1.83	0.00755				
	HRGEC	-3.32	2.4e-05				
NFATC1	HAEC	1.23	0.0274	Yes			(18, 19)
	HPAEC	1.75	0.0044				
	HRGEC	2.91	1.24e-05				
PPARG	HAEC	-2.39	0.00016		Yes	Heart/muscle	(9, 18, 19)
SOCS1	HAEC	-1.94	0.000891	YES			
	HCAEC	-2.25	0.00151				
	HCMVEC	-1.47	0.0104				
	HPMVEC	-2.39	9.7e-05				
TAL1	not HLSEC	1.35	0.0263		Yes	Lowest in liver	(18, 19)
	HCAEC	1.78	0.0194				
	HPAEC	2.28	0.00111				
	HPMVEC	1.34	0.0379				
	HRGEC	2.84	8.4e-05				
TCF4	HCAEC	1.49	0.0178		Yes	lowest in liver	(18, 19)
	HRGEC	2.23	0.000171				
TGFB1	HCAEC	-2.84	0.00349	Yes			
	HCMVEC	-2.47	0.00295				
	HPMVEC	-1.73	0.0337				
THY1	not HLSEC	-4.04	0.00821	Yes*			(18)
	HAEC	-6.64	1.7e-11				
	HCAEC	-5.64	1.1e-05				
	HCMVEC	-5.05	4.8e-06				
	HPAEC	-9.15	2.2e-10				
	HPMVEC	-4.32	3.7e-05				
	HRGEC	-4.32	8.5e-05				
TNFAIP3	HRGEC	2.34	0.000871	Yes	Yes	Liver	(17, 18, GDS4777, GSE47067)
TNFAIP6	not HLSEC	-3.94	9.8e-05	No	Yes	Liver	(18, GDS4777)
	HAEC	-4.05	6.5e-06				
	HCAEC	-4.32	2.4e-05				
	HCMVEC	-3.34	1.6e-05				
	HPMVEC	-4.05	6.3e-06				
	HRGEC	-3.18	5.3e-04				
TNFSF10 (trail)	HCAEC	2.08	0.0132	Yes	Yes	Lowest in liver	(9, 18, 19)
	HPMVEC	1.94	0.00724				
	HRGEC	1.67	0.0245				

**Table 2.** List of differentially expressed genes among human endothelial cells from different anatomic origins, and results of confirmatory analysis in public datasets of endothelial cell heterogeneity. \*Indicates enrichment may not be due to Endothelial cells, as gene may likely be expressed within leukocyte compartment. "Yes" in bold indicates gene may be endothelial-associated.

with Accutase, then stained with Panel 4 (Table S4) in FACS buffer (PBS + 2% HI-FBS) for 45 min at 4 °C, washed and analyzed by flow cytometry (BD Fortessa). Compensation was performed using compensation beads (BD Biosciences). The gating strategy is shown in Figure S2a–e. Gating controls showing reproducibility and relative frequencies of endothelial cells and PBMC subsets in the input fractions are provided in Figure S2f–h. After gating out debris by FSC/SSC, leukocytes were distinguished from endothelium by gating CD11a (negative on endothelial cells) and CD31 or CD105 (bright on endothelial cells). Non-endothelial cells were then subset gated based on CD3 (T cells), CD56 (NK cells), CD19 (B cells), CD14 (monocytes), and HLA-DR (B cells and mono-



cytes). We observed that monocyte-endothelial cell doublets were formed when endothelium was activated with TNF $\alpha$ , but which were not present in the input fractions or in cocultures with unstimulated endothelial cells, forming double positive CD11a + CD105 + events that were CD14<sup>high</sup>.

**HLA antibody and complement stimulation.** Fully human and chimeric human HLA monoclonal antibodies<sup>47</sup> and patient sera were tested for binding against EC by flow cytometry (Figure S6). Based on these experiments, human and chimeric anti-HLA IgG were diluted as a mixture in M199 to final concentration of 0.5  $\mu$ g/mL per antibody (HLA I IgG1 + HLA-A2/A28 IgG1 + HLA-A3/A11 IgG1 + HLA-A2/B17 IgG1). Non-sensitized and alloantibody-containing sera were diluted into M199. Human serum complement was stored at  $-80^{\circ}\text{C}$ , and on the day of experiments rapidly thawed at  $37^{\circ}\text{C}$  until only a sliver of ice remained, then transferred immediately to ice. Freshly thawed human serum complement (intact or inactivated) was added to HLA antibody diluted in M199 to a final concentration of 25% of complement within 20 min of thawing (based on preliminary experiments). Then, HLA antibodies which bind to cells and human serum complement together were added to endothelial monolayers and experimental incubations were carried out at  $37^{\circ}\text{C}$ . For 48-well plates, a total volume of 250  $\mu$ L was added; for 24-well plates, 500  $\mu$ L was added.

**Targeted gene expression analysis.** RNA was diluted to 20 ng/ $\mu$ L in RNase and DNase-free water. To determine inducible changes in gene expression in cultured cells, confluent endothelial cells were stimulated for 4 h in M199 + 10% FBS with each stimulus, or left untreated in M199 + 10% FBS. Lysates of cultured endothelial cells were prepared by pelleting at 300xg, aspirating all supernatant, resuspending in RLT buffer (Qiagen) in nuclease-free tubes and homogenized by vortexing for 1 min. A ratio of 1  $\mu$ L of RLT buffer per approximately 6,500 cells was used.

mRNA expression of immunology-related genes was assessed using nCounter (NanoString, Human Immunology Panel, 579 genes), performed by the UCLA Center for Systems Biomedicine. Data were analyzed using NSolver software (NanoString Technologies, Seattle, WA). Differential gene expression data comparing each EC type to HLSEC are available in Table S6.

**Chemokine detection.** Supernatants from stimulated endothelial cells were collected at the end of each experiment. 38 cytokines and chemokines were measured in conditioned media using the multiplexed Milliplex Human Cytokine/Chemokine panel (Millipore) and performed by the UCLA Immune Assessment Core. Secretion of IP-10 (CXCL10, R&D DY266-05), I-TAC (CXCL11, R&D Systems #DY672), CCL5 (RANTES, R&D Systems #DRN00B), CCL20 (LARC, R&D Systems #DY360-05) and CXCL8 (IL-8, R&D Systems #D8000C) into conditioned media were measured by ELISA according to the manufacturer's recommendations. Generation of C5a in cell culture supernatants was measured by ELISA (R&D Systems #DY2037) according to the vendor's protocol.

**Flow cytometry.** Endothelial cells were seeded at confluence and allowed to rest overnight in complete medium. Stimulated endothelial cells were washed once with PBS without Ca<sup>2+</sup> or Mg<sup>2+</sup>, detached with room temperature Accutase (Innovative Cell Technologies), and resuspended in FACS buffer (cold PBS + 2% FBS + 1% NaN<sub>3</sub>). Cell surface expression of adhesion molecules was determined using Panel 1 or Panel 2 described in Table S4. For complement detection, confluent EC exposed to antibodies and human complement at  $37^{\circ}\text{C}$  were detached with Accutase and stained with Panel 3 (Table S4) first with rabbit anti-human SC5b-9, followed by anti-rabbit-PE and mouse anti-human IgG-BV510 secondary antibodies. Cells were then acquired by flow cytometry (BD Fortessa). SC5b-9 is an integral component of the terminal complement membrane attack complex; deposition of this protein complex on the surface of cells represents evidence for advanced complement activation at the level of the target cell.

**Publicly available datasets and data availability.** Cardiac allograft biopsy microarray data [GSE124897]<sup>17</sup> was downloaded from the NCBI GEO website (<https://www.ncbi.nlm.nih.gov/gds>). Other data were also downloaded from GEO, from investigator-developed databases or using the Bioinformatics Array Research Tool for microarray data (<http://igc1.salk.edu:3838/bart/>)<sup>48</sup> and analyzed using GEO2R. Other datasets referenced in this study were also downloaded from GEO (<http://igc1.salk.edu:3838/bart/>)<sup>48</sup>, or from investigator-developed databases (Table S5, S7 and S8).

Cardiac allograft biopsy microarray data [GSE124897] included 889 subjects and 49,395 probes. The test and training datasets had the same distribution of rejection versus normal and the type of rejection (Table 1).

Bulk transcriptome data from 1) freshly isolated endothelium from mouse heart, liver and brain [GSE48209,<sup>49</sup>]; 2) ribo-tagged mouse EC from heart and lung [GSE136848,<sup>12</sup>]; 3) mouse transcriptome EC from heart, kidney, liver and lung [GSE138629,<sup>11</sup>] were downloaded using BART and analyzed. Genes enriched in endothelial cells from mouse kidney, liver, and lung were queried from (<https://marksabbagh.shinyapps.io/vectrdb/>)<sup>25</sup>. Single cell RNA sequencing from whole mouse organs: Gene expression data of heart endothelial cells, endocardial cells, kidney capillary endothelial cells, lung endothelial cells and endothelial cell of hepatic sinusoids were downloaded from [<https://tabula-muris.ds.czbiohub.org/>]<sup>26</sup>. Genes that were specific markers of heart, lung, kidney and liver endothelial cells compared with all other organs were queried; and genes enriched within vascular subcompartments within each organ, using the Marker Set tool at ([https://endotheliomics.shinyapps.io/ec\\_atlas/](https://endotheliomics.shinyapps.io/ec_atlas/))<sup>13</sup>.

Genes that were found in human aortic endothelial cells but not in liver endothelial cells were queried by selecting for HAoEC—Heart—Normal and Specific; and HHSEC—Liver—Normal and Specific. This yielded 1946 genes specific in HAEC but not HLSEC; and 1451 genes specific in HLSEC but not HAEC, with no gene overlap.

The lists can be found in Table S7 and Table S8, respectively. <http://angiogenes.uni-frankfurt.de/><sup>24</sup>. Other studies of human endothelial cells included: Microarray study of cultured (mix of commercial and fresh isolate) human aortic, coronary artery, iliac arterial, pulmonary artery, iliac vein, and pulmonary vein ECs, human hepatic artery, hepatic vein ECs GSE43475 (GDS4777)<sup>45</sup>; and GSE114607 human fetal organs<sup>14</sup>. Differentially expressed genes comparing heart (coronary + aortic) versus not heart (pulmonary and hepatic artery) and liver (hepatic artery) versus not liver (coronary, aortic and pulmonary artery) were queried for the top 250 DEGs using Geo2R.

**Analyses.** Heat maps and hierarchical clustering were generated using Morpheus (<https://software.broadinstitute.org/morpheus>). Graphs were generated in Prism (GraphPad Software, San Diego, CA). Differences between groups were determined by one way ANOVA followed by *t* test (GraphPad).

Cardiac allograft biopsy microarray data [GSE124897] were back transformed. Probes with standard deviation  $\geq 0.5$  or within the top 75 percentile mean were selected for further analyses, and the data was divided into training (75%) and test (25%) sets based on the distribution of rejection/normal and rejection type (Table 1). Next, a series of Wilcoxon testing was performed to find genes that are differentially expressed among rejection (y/n), next the *p* values were adjusted for false discovery rate (fdr), and the top 5000 probes with lowest q-value were selected for weighted gene co-expression network analyses (WGCNA) analyses. Backtransformed data were also analyzed for differences in individual gene expression by one way ANOVA followed by uncorrected Fisher's LSD *t* test (GraphPad).

Received: 17 September 2020; Accepted: 16 December 2020

Published online: 21 January 2021

## References

- Colvin, M. *et al.* OPTN/SRTR 2018 annual data report: heart. *Am. J. Transplant.* **20**(Suppl s1), 340–426. <https://doi.org/10.1111/ajt.15676> (2020).
- Kwong, A. *et al.* OPTN/SRTR 2018 annual data report: liver. *Am. J. Transplant.* **20**(Suppl s1), 193–299. <https://doi.org/10.1111/ajt.15674> (2020).
- Valapour, M. *et al.* OPTN/SRTR 2018 annual data report: lung. *Am. J. Transplant.* **20**(Suppl s1), 427–508. <https://doi.org/10.1111/ajt.15677> (2020).
- Issa, F., Schiopu, A. & Wood, K. J. Role of T cells in graft rejection and transplantation tolerance. *Expert Rev. Clin. Immunol.* **6**, 155–169. <https://doi.org/10.1586/eci.09.64> (2010).
- Salehi, S. & Reed, E. F. The divergent roles of macrophages in solid organ transplantation. *Curr. Opin. Organ. Transplant.* **20**, 446–453. <https://doi.org/10.1097/MOT.000000000000209> (2015).
- Shimizu, A., Yamada, K., Sachs, D. H. & Colvin, R. B. Intra-graft events preceding chronic renal allograft rejection in a modified tolerance protocol. *Kidney Int.* **58**, 2546–2558. <https://doi.org/10.1046/j.1523-1755.2000.00440.x> (2000).
- Halloran, P. F. Immunosuppressive drugs for kidney transplantation. *N. Engl. J. Med.* **351**, 2715–2729. <https://doi.org/10.1056/NEJMra033540> (2004).
- Briscoe, D. M. *et al.* Predictive value of inducible endothelial cell adhesion molecule expression for acute rejection of human cardiac allografts. *Transplantation* **59**, 204–211 (1995).
- Scott, D. W., Vallejo, M. O. & Patel, R. P. Heterogenic endothelial responses to inflammation: role for differential N-glycosylation and vascular bed of origin. *J. Am. Heart Assoc.* **2**, e000263. <https://doi.org/10.1161/JAHA.113.000263> (2013).
- Chi, J. T. *et al.* Endothelial cell diversity revealed by global expression profiling. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 10623–10628. <https://doi.org/10.1073/pnas.1434429100> (2003).
- Cleuren, A. C. A. *et al.* The in vivo endothelial cell transcriptome is highly heterogeneous across vascular beds. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 23618–23624. <https://doi.org/10.1073/pnas.1912409116> (2019).
- Jambusaria, A. *et al.* Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation. *Elife* <https://doi.org/10.7554/eLife.51413> (2020).
- Kalucka, J. *et al.* Single-cell transcriptome atlas of murine endothelial cells. *Cell* **180**, 764–779. <https://doi.org/10.1016/j.cell.2020.01.015> (2020).
- Marcu, R. *et al.* Human organ-specific endothelial cell heterogeneity. *iScience* **4**, 20–35. <https://doi.org/10.1016/j.isci.2018.05.003> (2018).
- Nakato, R. *et al.* Comprehensive epigenome characterization reveals diverse transcriptional regulation across human vascular endothelial cells. *Epigenet. Chromatin* **12**, 77. <https://doi.org/10.1186/s13072-019-0319-0> (2019).
- Nolan, D. J. *et al.* Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration. *Dev. Cell* **26**, 204–219. <https://doi.org/10.1016/j.devcel.2013.06.017> (2013).
- Parkes, M. D. *et al.* An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms. *J. Heart Lung Transplant.* **38**, 636–646. <https://doi.org/10.1016/j.healun.2019.01.1318> (2019).
- da Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protoc.* **4**, 44–57. <https://doi.org/10.1038/nprot.2008.211> (2009).
- Albrecht, E. A. *et al.* C5a-induced gene expression in human umbilical vein endothelial cells. *Am. J. Pathol.* **164**, 849–859. [https://doi.org/10.1016/S0002-9440\(10\)63173-2](https://doi.org/10.1016/S0002-9440(10)63173-2) (2004).
- Jane-Wit, D. *et al.* Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-kappaB signaling in endothelial cells. *Circulation* **128**, 2504–2516. <https://doi.org/10.1161/CIRCULATIONAHA.113.002972> (2013).
- Kilgore, K. S. *et al.* Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. *Am. J. Pathol.* **150**, 2019–2031 (1997).
- Valenzuela, N. M. *et al.* Complement-mediated enhancement of monocyte adhesion to endothelial cells by HLA antibodies, and blockade by a specific inhibitor of the classical complement cascade, TNT003. *Transplantation* **101**, 1559–1572. <https://doi.org/10.1097/TP.0000000000001486> (2017).
- Xie, C. B. *et al.* Complement membrane attack complexes assemble NLRP3 inflammasomes triggering IL-1 activation of IFN-gamma-primed human endothelium. *Circ. Res.* **124**, 1747–1759. <https://doi.org/10.1161/CIRCRESAHA.119.314845> (2019).
- Muller, R. *et al.* ANGIOGENES: knowledge database for protein-coding and noncoding RNA genes in endothelial cells. *Sci. Rep.* **6**, 32475. <https://doi.org/10.1038/srep32475> (2016).
- Sabbagh, M. F. *et al.* Transcriptional and epigenomic landscapes of CNS and non-CNS vascular endothelial cells. *Elife* <https://doi.org/10.7554/eLife.36187> (2018).

26. Tabula Muris, C. *et al.* Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. *Nature* **562**, 367–372. <https://doi.org/10.1038/s41586-018-0590-4> (2018).
27. Carlos, T. *et al.* Vascular cell adhesion molecule-1 is induced on endothelium during acute rejection in human cardiac allografts. *J. Heart Lung Transplant.* **11**, 1103–1108 (1992).
28. Lemstrom, K., Koskinen, P. & Hayry, P. Induction of adhesion molecules on the endothelia of rejecting cardiac allografts. *J. Heart Lung Transplant.* **14**, 205–213 (1995).
29. Steinhoff, G. *et al.* Distinct expression of cell-cell and cell-matrix adhesion molecules on endothelial cells in human heart and lung transplants. *J. Heart Lung Transplant.* **14**, 1145–1155 (1995).
30. Steinhoff, G., Behrend, M., Schrader, B., Duijvestijn, A. M. & Wonigeit, K. Expression patterns of leukocyte adhesion ligand molecules on human liver endothelia. Lack of ELAM-1 and CD62 inducibility on sinusoidal endothelia and distinct distribution of VCAM-1, ICAM-1, ICAM-2, and LFA-3. *Am. J. Pathol.* **142**, 481–488 (1993).
31. Bhasin, M. *et al.* Bioinformatic identification and characterization of human endothelial cell-restricted genes. *BMC Genom.* **11**, 342. <https://doi.org/10.1186/1471-2164-11-342> (2010).
32. Dumas, S. J. *et al.* Single-cell RNA sequencing reveals renal endothelium heterogeneity and metabolic adaptation to water deprivation. *J. Am. Soc. Nephrol.* **31**, 118–138. <https://doi.org/10.1681/ASN.2019080832> (2020).
33. Feng, W., Chen, L., Nguyen, P. K., Wu, S. M. & Li, G. Single cell analysis of endothelial cells identified organ-specific molecular signatures and heart-specific cell populations and molecular features. *Front. Cardiovasc. Med.* **6**, 165. <https://doi.org/10.3389/fcvm.2019.00165> (2019).
34. Rius, C. *et al.* Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II. *Arterioscler. Thromb. Vasc. Biol.* **33**, 96–104. <https://doi.org/10.1161/ATVBAHA.112.254870> (2013).
35. Viemann, D. *et al.* TNF induces distinct gene expression programs in microvascular and macrovascular human endothelial cells. *J. Leukoc. Biol.* **80**, 174–185. <https://doi.org/10.1189/jlb.0905530> (2006).
36. Lim, Y. C. *et al.* Heterogeneity of endothelial cells from different organ sites in T-cell subset recruitment. *Am. J. Pathol.* **162**, 1591–1601. [https://doi.org/10.1016/S0002-9440\(10\)64293-9](https://doi.org/10.1016/S0002-9440(10)64293-9) (2003).
37. Jongman, R. M. *et al.* Partial deletion of Tie2 affects microvascular endothelial responses to critical illness in a vascular bed and organ-specific way. *Shock* **51**, 757–769. <https://doi.org/10.1097/SHK.0000000000001226> (2019).
38. Sana, T. R., Janatpour, M. J., Sathe, M., McEvoy, L. M. & McClanahan, T. K. Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. *Cytokine* **29**, 256–269. <https://doi.org/10.1016/j.cyto.2004.11.003> (2005).
39. Invernici, G. *et al.* Human microvascular endothelial cells from different fetal organs demonstrate organ-specific CAM expression. *Exp. Cell Res.* **308**, 273–282. <https://doi.org/10.1016/j.yexcr.2005.04.033> (2005).
40. Campbell, J. J. *et al.* Chemokines and the arrest of lymphocytes rolling under flow conditions. *Science* **279**, 381–384. <https://doi.org/10.1126/science.279.5349.381> (1998).
41. Gerszten, R. E. *et al.* MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. *Nature* **398**, 718–723. <https://doi.org/10.1038/19546> (1999).
42. Monsinjon, T. *et al.* Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. *FASEB J* **17**, 1003–1014. <https://doi.org/10.1096/fj.02-0737com> (2003).
43. Skeie, J. M., Fingert, J. H., Russell, S. R., Stone, E. M. & Mullins, R. F. Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. *Invest. Ophthalmol. Vis. Sci.* **51**, 5336–5342. <https://doi.org/10.1167/iiov.10-5322> (2010).
44. Sartain, S. E., Turner, N. A. & Moake, J. L. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. *J. Biol. Chem.* **293**, 7195–7208. <https://doi.org/10.1074/jbc.RA118.002639> (2018).
45. Aranguren, X. L. *et al.* Unraveling a novel transcription factor code determining the human arterial-specific endothelial cell signature. *Blood* **122**, 3982–3992. <https://doi.org/10.1182/blood-2013-02-483255> (2013).
46. Yeh, M. *et al.* Increased transcription of IL-8 in endothelial cells is differentially regulated by TNF-alpha and oxidized phospholipids. *Arterioscler. Thromb. Vasc. Biol.* **21**, 1585–1591. <https://doi.org/10.1161/hq1001.097027> (2001).
47. Mulder, A. *et al.* Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation. *Mol. Immunol.* **47**, 809–815. <https://doi.org/10.1016/j.molimm.2009.10.004> (2010).
48. Amaral, M. L., Erikson, G. A. & Shokhirev, M. N. BART: bioinformatics array research tool. *BMC Bioinform.* **19**, 296. <https://doi.org/10.1186/s12859-018-2308-x> (2018).
49. Coppiello, G. *et al.* Meox2/Tcf15 heterodimers program the heart capillary endothelium for cardiac fatty acid uptake. *Circulation* **131**, 815–826. <https://doi.org/10.1161/CIRCULATIONAHA.114.013721> (2015).

## Acknowledgements

The authors hereby express their thanks for the cooperation of OneLegacy and all the organ and tissue donors and their families, for giving the gift of life and the gift of knowledge, by their generous donation. The authors would also like to thank One Lambda/ThermoFisher for providing monoclonal HLA antibodies. The authors would also like to acknowledge Dr. Maura Rossetti (UCLA) and the UCLA Immune Assessment Core for guidance on multicolor flow cytometry panels; as well as Gemalene Sunga (UCLA IAC) for Luminex assays, and Dr. Emmanuelle Faure at the UCLA IMT Core/Center for Systems Biomedicine which is supported by CURE/P30 DK041301, for Nanostring services.

## Author contributions

H.G. participated in conducting experiments, analysis of data, data curation, and preparation of data for presentation in this manuscript, and gave final approval of the manuscript. T.R. participated in data collection and formal data analysis, participated in critical review and gave final approval of the manuscript. N.Y. participated in data collection and formal data analysis, participated in critical review and gave final approval of the manuscript. S.H. contributed key reagents and participated in critical review of the manuscript, and gave final approval of the manuscript. A.M. contributed key reagents and participated in critical review of the manuscript, and gave final approval of the manuscript. D.A.E. participated in supervision of research execution, design of analysis approaches, participated in critical review and gave final approval of the manuscript. N.M.V. was responsible for developing the overarching research goals and aims, developing and planning the methodology used herein, supervising research execution, conducting experiments, analysis of data, data curation, preparation of data presentation, and writing of the manuscript, and gave final approval of the manuscript.

### Funding

This work was funded by the Norman E. Shumway Career Development Award from Enduring Hearts and the International Society for Heart and Lung Transplantation (to NMV). The funding agency had no role in the collection of data, analysis or interpretation.

### Competing interests

The authors declare no competing interests.

### Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-020-80102-w>.

**Correspondence** and requests for materials should be addressed to N.M.V.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021